【Abstract】 Objective To investigate the effects of aspirin plus ticagrelor on the inflammatory factors in patients with coronary heart disease after percutaneous coronary intervention (PCI). Methods 120 patients with coronary heart disease underwent PCI from May 2017 to March 2018 in our hospital were selected, and randomly divided into the observation group(n=60) treated with aspirin plus ticagrelor for 12 months and control group (n=60) treated with aspirin plus clopidogrel for 12 months. The levels inflammatory factors and the occurrence of cardiovascular adverse events were compared. Results The levels of the CRP, TNFalpha and IL6 in the observation group were significantly lower than those in the control group at 24 hours, 1 week and 1 month after PCI(P＜0.05). After one year followup, the incidence of adverse cardiovascular events in the observation group was 3.33%, which was significantly lower than that in the control group (13.33%)(P＜0.05). However, there was no significant difference in the incidence of minor bleeding events and drugrelated adverse reactions between the two groups (P＞0.05). Conclusion Asprin and Ticagrelor has a significant clinical effect in the treatment of patients with coronary heart disease after PCI. It can effectively alleviate inflammation and reduce the occurrence of cardiovascular adverse events, while it may increase the risk of bleeding. Therefore, clinical treatment regimen should be made combining with patients′ actual condition.